Kent Thudium

Bristol-Myers Squibb (United States) — United States

Medicine · Health Sciences

14h-index3.2kcitations80works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Radiopharmaceutical Chemistry and Applications(40), Monoclonal and Polyclonal Antibodies Research(35), Cancer Immunotherapy and Biomarkers(34), Nanoparticle-Based Drug Delivery(30), Immunotherapy and Immune Responses(20)

Publications80 total

Data from Preclinical Characterization of Relatlimab, a Human LAG-3–Blocking Antibody, Alone or in Combination with Nivolumab
2023Open Access
Data from Preclinical Characterization of Relatlimab, a Human LAG-3–Blocking Antibody, Alone or in Combination with Nivolumab
2023Open Access
Supplementary Data from Preclinical Characterization of Relatlimab, a Human LAG-3–Blocking Antibody, Alone or in Combination with Nivolumab
2023Open Access
Supplementary Data from Preclinical Characterization of Relatlimab, a Human LAG-3–Blocking Antibody, Alone or in Combination with Nivolumab
2023Open Access
Supplementary Figure 5 from <i>In Vitro</i> Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and <i>In Vivo</i> Toxicology in Non-Human Primates
2023Open Access
Data from <i>In Vitro</i> Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and <i>In Vivo</i> Toxicology in Non-Human Primates
2023Open Access
Supplementary Figure 2 from <i>In Vitro</i> Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and <i>In Vivo</i> Toxicology in Non-Human Primates
2023Open Access
Data from <i>In Vitro</i> Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and <i>In Vivo</i> Toxicology in Non-Human Primates
2023Open Access
Supplementary Figure 4 from <i>In Vitro</i> Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and <i>In Vivo</i> Toxicology in Non-Human Primates
2023Open Access
Supplementary Figure 1 from <i>In Vitro</i> Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and <i>In Vivo</i> Toxicology in Non-Human Primates
2023Open Access
Supplementary Figure 2 from <i>In Vitro</i> Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and <i>In Vivo</i> Toxicology in Non-Human Primates
2023Open Access
Supplementary Figure 3 from <i>In Vitro</i> Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and <i>In Vivo</i> Toxicology in Non-Human Primates
2023Open Access
Supplementary Figure 5 from <i>In Vitro</i> Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and <i>In Vivo</i> Toxicology in Non-Human Primates
2023Open Access
Supplementary Figure 4 from <i>In Vitro</i> Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and <i>In Vivo</i> Toxicology in Non-Human Primates
2023Open Access
Supplementary Figure 1 from <i>In Vitro</i> Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and <i>In Vivo</i> Toxicology in Non-Human Primates
2023Open Access
Supplementary Figure Legends from <i>In Vitro</i> Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and <i>In Vivo</i> Toxicology in Non-Human Primates
2023Open Access
Supplementary Figure Legends from <i>In Vitro</i> Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and <i>In Vivo</i> Toxicology in Non-Human Primates
2023Open Access
Supplementary Figure 3 from <i>In Vitro</i> Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and <i>In Vivo</i> Toxicology in Non-Human Primates
2023Open Access
Supplementary Figure 5 from Elective Nodal Irradiation Attenuates the Combinatorial Efficacy of Stereotactic Radiation Therapy and Immunotherapy
2023Open Access
Supplementary Data from An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid Tumors
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Alan J. Korman(41), Mark Selby(26), Michael Quigley(18), Ignacio Melero(17), Megan Raymond(16), Gennaro Dito(16), Dominic Kabbabe(16), Ed Hilt(16), Martin Gutierrez(16), Anna Spreafico(16), Richard D. Carvajal(16), Anthony J. Olszanski(16), Christina Milburn(16), Paula M. Fracasso(16), Praveen Aanur(16), Shih-Min A. Huang(16), Xiao Shao(15), Yongliang Sun(15), Michael Ong(15), Yang Zheng(15)